SPRY | ARS Pharmaceuticals, Inc. Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	10.83 - 11.56
52 Week Range	5.10 - 18.51
Beta	2.24
Implied Volatility	104.11%
IV Rank	4.85%
Day's Volume	2,508,820
Average Volume	1,064,993
Shares Outstanding	97,185,500
Market Cap	1,086,533,890
Sector	Healthcare
Industry	Biotechnology
IPO Date	2020-12-04

Valuation
Profitability
Growth
Health
P/E Ratio	-22.36
Forward P/E Ratio	N/A
EPS	-0.50
1YR Price Target	N/A
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	24
Country	USA
Website	SPRY

ARS Pharmaceuticals, Inc. develops ARS-1, a novel intranasal epinephrine spray with absorption technology for patients and their families at-risk of severe allergic reactions to food, medications, and insect bites. Its product includes Neffy, a low-dose intranasal epinephrine nasal spray. The company was incorporated in 2015 and is based in San Diego, California.

SPRY's peers: ZURA, ANNX, ICVX, INAB, WVE, PALI, CFRX, ALLR, CNSP, WINT, IMMX, HEPA, FRLN, AVRO, CGTX, TFFP, TCRX, CUE, DRMA

*Chart delayed

Analyzing fundamentals for SPRY we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is desperately bad and Health is weak. For more detailed analysis please see SPRY Fundamentals page.

Watching at SPRY technicals we can see that long-term trend is bearish, the same as bearish middle-term trend, as well as bearish short-term trend. More technicals details can be found on SPRY Technicals page.